Ingram Micro Cloud Now Offers AWS Cloud Services in Hungary and Poland as Part of Continued Global Expansion
12.11.2021 11:00:00 EET | Business Wire | Press release
Ingram Micro Cloud today announced that it is now distributing a full range of Amazon Web Services, Inc. (AWS) products and services to its reseller network in Hungary and Poland. The move bolsters the global offering of Ingram Micro’s Cloud Marketplace, one of the world’s most comprehensive and broadly adopted set of cloud solutions.
Ingram Micro Cloud, an AWS Advanced Consulting Partner and AWS Distributor, announced its global Strategic Collaboration Agreement (SCA) with AWS in March this year. One of the central objectives of the agreement between the business leaders is extending the global reach and footprint of AWS and its partners. As part of this global expansion, Ingram Micro Cloud is now delivering a complete portfolio of AWS solutions to resellers in Hungary and Poland, in addition to its recent launches in France, Mexico, Australia, and New Zealand, which were part of a series of authorizations in 2021. As a result of the SCA with AWS, Ingram Micro expects its large network of partners to see new opportunities to meet customer needs and expand their infrastructure as a service (IaaS) business.
"The distribution alliance between Ingram Micro Cloud and AWS in our region is a great strategic milestone for us,” said Attila Virágh, Managing Director at Ingram Micro Hungary. “Teaming further with AWS brings tremendous opportunity and additional business value to our channel partners within the cloud ecosystem by helping them execute at scale, and quickly meet the business needs of their customers.”
“I’m happy to see AWS joining our marketplace offering in Central and Eastern Europe. I am confident this relationship will significantly contribute to the acceleration of as-a-service models and customers’ cloud migration,” said Jacek Jedraszka, Managing Director at Ingram Micro Poland.
AWS and Ingram Micro Cloud are working together to bolster Ingram Micro Cloud’s current skills and offerings, as well as develop new resources to support channel partners in managing end customers. Ingram Micro Cloud currently provides an AWS Cloud Center of Excellence (CCoE) team with 200+ AWS Certifications, AWS Professional Services, AWS Managed Services, AWS Well-Architected Services, AWS Operations and Billing Services, and more.
Ingram Micro Cloud also covers a wide range of partner enablement and support initiatives to help AWS Partners build an AWS practice through its partner programs, which provide end-to-end engagement models for Ingram Micro Cloud to enable systems integrators (SIs) and independent software vendors (ISVs) in their journey on the cloud.
“We are pleased to differentiate our broad portfolio of cloud services with the addition of AWS on our Cloud Marketplace,” said Nora Papp, Head of Cloud for Central and Eastern Europe at Ingram Micro. “Through this important expansion of pioneering solutions and services, Ingram Micro Cloud is offering our reseller partners the seamless capability to build a successful AWS practice and deliver greater value to their customers.”
Further information about Ingram Micro Cloud’s AWS offerings can be found here.
About Ingram Micro Cloud
Ingram Micro Cloud brings together innovators and problem solvers to help the world accomplish more. It facilitates and manages the cloud’s complex digital value chain—all powered by CloudBlue technology. Ingram Micro Cloud operates in 76 countries with over 55,000 reseller partners, and its Cloud Marketplace serves 17.2 million seats, offering more than 120 cloud solutions. With unmatched global reach, easy access to automated go-to-market and integration tools, deep technical expertise, and a curated selection of scalable SaaS and IaaS solutions, Ingram Micro Cloud helps vendors, resellers and managed service providers by offering More as a Service. Detailed information is available at www.IngramMicroCloud.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211112005051/en/
Contact information
Peter Toth
Business Operations Manager
Ingram Micro Hungary
peter.toth2@ingrammicro.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom